EXPRESS MAIL LABEL: EL474254618US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re:

Patent Application of

Douglas Cines, et al.

Appln. No.:

Not yet assigned

Filed:

April 6, 2000

For:

COMPOSITIONS AND METHODS FOR : Attorney Docket

PROMOTING INTERNALIZATION

: No. 9596-67U1

AND DEGRADATION OF UROKINASE-:

(K1668)

TYPE PLASMINOGEN ACTIVATOR

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

(X)	I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the
	contents of the paper and computer readable copies of the Sequence Listing, submitted in
	accordance with 37 C.F.R. §1.821(c) and (e), respectively are the same.

()	I hereby state that the submission filed in accordance with 37 C.F.R. §1.821(g) does not
	include new matter

()	I hereby state that the submission filed in accordance with 37 C.F.R. §1.821(h) does not
	include new matter or go beyond the disclosure in the international application as filed.

()	I hereby state that the amendments, made in accordance with 37 C.F.R. §1.825(a),
	included in the initial/substitute sheet(s) of the Sequence Listing are supported in the
	application, as filed, at pages I hereby state that the substitute sheets(s) of the
	Sequence Listing does(do) not include new matter.

I hereby state that the substitute copy of the computer readable form, submitted in () accordance with 37 C.F.R. §1.825(b), is the same as the amended Sequence Listing.

50171 v150171 v1

() I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(d), contains identical data to that originally filed.

Respectfully submitted,

DOUGLAS CINES, et al.

W00 I

ву:

GARY D. COLBY, M.D., J.D.

Registration No. 40,961

AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.

One Commerce Square

2005 Market Street - Suite 2200

Philadelphia, PA 19103 Telephone: (215) 965-1200

Direct Dial: (215) 965-1285

Facsimile: (215) 965-1210

E-Mail: gcolby@akingump.com

GDC/ark